Last reviewed · How we verify
Oxybuprocaine SDU
Oxybuprocaine is a local anesthetic that blocks sodium channels in nerve cell membranes to prevent pain signal transmission.
Oxybuprocaine is a local anesthetic that blocks sodium channels in nerve cell membranes to prevent pain signal transmission. Used for Topical ophthalmic anesthesia for diagnostic procedures, Topical ophthalmic anesthesia for minor ocular surgery.
At a glance
| Generic name | Oxybuprocaine SDU |
|---|---|
| Sponsor | Medical University of Vienna |
| Drug class | Local anesthetic |
| Target | Voltage-gated sodium channels |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Oxybuprocaine works by inhibiting sodium influx through voltage-gated sodium channels in nerve fibers, thereby preventing depolarization and the generation of action potentials. This reversible blockade of neural conduction results in local anesthesia at the site of application. It is commonly used as a topical ophthalmic anesthetic for diagnostic and minor surgical procedures.
Approved indications
- Topical ophthalmic anesthesia for diagnostic procedures
- Topical ophthalmic anesthesia for minor ocular surgery
Common side effects
- Corneal epithelial toxicity
- Transient eye irritation
- Allergic conjunctivitis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxybuprocaine SDU CI brief — competitive landscape report
- Oxybuprocaine SDU updates RSS · CI watch RSS
- Medical University of Vienna portfolio CI